Literature DB >> 25103609

Nocturia and its impact on health-related quality of life and health care seeking behaviour in German community-dwelling men aged 50 years or older.

Matthias Oelke1, Birgitt Wiese, Richard Berges.   

Abstract

PURPOSE: To evaluate the prevalence of nocturia/nocturnal voiding frequency and its impact on overall physical and mental health status in German community-dwelling men and determine which lower urinary tract symptom (LUTS) is responsible for medical consultations in the 2-year follow-up period.
METHODS: A sample of German men aged 50-80 years from a community-dwelling study was chosen for re-evaluation 2 years after initial assessment. Men were clinically investigated and completed the International Prostate Symptom Score, American Urology Association-Symptom Problem Index (AUA-SPI), and the Short-Form Health Survey (SF-12).
RESULTS: In total, 1,562 men were eligible for analysis. Mean nocturnal voiding frequency was 2.3 for all men and increased with ageing. SF-12 data indicated that physical but not mental health status was lower than in the average population. LUTS severity reduced both physical and mental health status (p < 0.001). Clinically relevant nocturia (≥ 2 voids/night) was present in 43 % of men and reduced both physical and mental health status (p < 0.001), whereas both HRQoL scales were not significantly reduced in men without or only one nocturnal void. In multivariate regression analysis using patient-reported bother (AUA-SPI) from LUTS, only bother from nocturnal voiding was significantly associated with medical consultations in the investigated 2-year follow-up period (odds ratio 2.6; 95 % confidence interval 1.6-4.2; p < 0.001).
CONCLUSIONS: Our study confirmed that nocturnal voiding is highly prevalent in community-dwelling men and reduce both physical and mental health status. Bother from nocturnal voiding is the most relevant component of LUTS responsible for medical consultations in German men.

Entities:  

Mesh:

Year:  2014        PMID: 25103609     DOI: 10.1007/s00345-014-1374-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

1.  The standardisation of terminology in nocturia: report from the Standardisation Sub-committee of the International Continence Society.

Authors:  Philip van Kerrebroeck; Paul Abrams; David Chaikin; Jenny Donovan; David Fonda; Simon Jackson; Poul Jennum; Theodore Johnson; Gunnar Lose; Anders Mattiasson; Gary Robertson; Jeff Weiss
Journal:  Neurourol Urodyn       Date:  2002       Impact factor: 2.696

2.  The role of nocturia in the quality of life of men with lower urinary tract symptoms.

Authors:  Jens Peter Nørgaard
Journal:  BJU Int       Date:  2010-04       Impact factor: 5.588

3.  [Diagnostic and differential diagnosis of benign prostate syndrome (BPS): guidelines of the German Urologists].

Authors:  R Berges; K Dreikorn; K Höfner; S Madersbacher; M C Michel; R Muschter; M Oelke; O Reich; W Rulf; C Tschuschke; U Tunn
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639

4.  Perception of nocturia and medical consulting behavior among community-dwelling women.

Authors:  Fong-Ying Chen; Yu-Tzu Dai; Chih-Kuang Liu; Hong-Jeng Yu; Cheng-Ying Liu; Tony Hsiu-Hsi Chen
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2006-07-28

5.  The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  J E Ware; M Kosinski; B Gandek; N K Aaronson; G Apolone; P Bech; J Brazier; M Bullinger; S Kaasa; A Leplège; L Prieto; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

6.  Risk factors for disease progression in patients with lower urinary tract symptoms/benign prostatic hyperplasia (LUTS/BPH): a systematic analysis of expert opinion.

Authors:  F C Lowe; J Batista; R Berges; E Chartier-Kastler; G Conti; F Desgrandchamps; K Dreikorn; M O'Leary; M Perez; M Speakman; J Trachtenberg; A Tubaro; B Meesen; L Smets; H Stoevelaar
Journal:  Prostate Cancer Prostatic Dis       Date:  2005       Impact factor: 5.554

7.  The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries.

Authors:  Annie Hutchison; Richard Farmer; Katia Verhamme; Richard Berges; Remigio Vela Navarrete
Journal:  Eur Urol       Date:  2006-06-27       Impact factor: 20.096

8.  Patients' perceptions of quality of life after treatment for early prostate cancer.

Authors:  Jack A Clark; Thomas S Inui; Rebecca A Silliman; Barbara G Bokhour; Steven H Krasnow; Richard A Robinson; Monica Spaulding; James A Talcott
Journal:  J Clin Oncol       Date:  2003-10-15       Impact factor: 44.544

Review 9.  [Importance of nocturia and its impact on quality of sleep and quality of life in patient with benign prostatic hyperplasia].

Authors:  C Hernández Fernández; J Ristol Pont; E Estivill; J E Batista Miranda; M A López Aramburu
Journal:  Actas Urol Esp       Date:  2007-03       Impact factor: 0.994

10.  Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland.

Authors:  Kari A O Tikkinen; Theodore M Johnson; Teuvo L J Tammela; Harri Sintonen; Jari Haukka; Heini Huhtala; Anssi Auvinen
Journal:  Eur Urol       Date:  2009-04-03       Impact factor: 20.096

View more
  13 in total

1.  Latest developments in the assessment and treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: what is clinically relevant?

Authors:  Matthias Oelke
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

2.  Impact of desmopressin on nocturia due to nocturnal polyuria in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).

Authors:  Richard Berges; Klaus Höfner; Michael Gedamke; Matthias Oelke
Journal:  World J Urol       Date:  2014-08-19       Impact factor: 4.226

3.  Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies.

Authors:  Andrea Tubaro; José E Batista; Victor W Nitti; Sender Herschorn; Christopher R Chapple; Mary Beth Blauwet; Emad Siddiqui; Moses Huang; Matthias Oelke
Journal:  Ther Adv Urol       Date:  2017-05-10

4.  The diagnosis and treatment of lower urinary tract symptoms due to benign prostatic hyperplasia by primary care family physicians in Portugal.

Authors:  Júlio Fonseca; Carlos Martins da Silva
Journal:  Clin Drug Investig       Date:  2015-02       Impact factor: 2.859

5.  Lower urinary system symptoms and affecting factors in female students staying in a dormitory.

Authors:  Handan Özcan; Nezihe Kizilkaya Beji
Journal:  Rev Assoc Med Bras (1992)       Date:  2022-07       Impact factor: 1.712

6.  The change of IPSS 7 (nocturia) score has the maximum influence on the change of Qol score in patients with lower urinary tract symptoms.

Authors:  Woo Suk Choi; Hwancheol Son
Journal:  World J Urol       Date:  2018-08-02       Impact factor: 4.226

7.  Nocturia: state of the art and critical analysis of current assessment and treatment strategies.

Authors:  Matthias Oelke; Erika Adler; Daniela Marschall-Kehrel; Thomas R W Herrmann; Richard Berges
Journal:  World J Urol       Date:  2014-10       Impact factor: 4.226

Review 8.  Combination therapies for the management of nocturia and its comorbidities.

Authors:  Cenk Murat Yazici; Omer Kurt
Journal:  Res Rep Urol       Date:  2015-04-20

9.  Nocturia is often inadequately assessed, diagnosed and treated by physicians: results of an observational, real-life practice database containing 8659 European and US-American patients.

Authors:  Matthias Oelke; Peter Anderson; Robert Wood; Tove Holm-Larsen
Journal:  Int J Clin Pract       Date:  2016-10-17       Impact factor: 2.503

10.  Annual direct and indirect costs attributable to nocturia in Germany, Sweden, and the UK.

Authors:  Diana Weidlich; Fredrik L Andersson; Matthias Oelke; Marcus John Drake; Aino Fianu Jonasson; Julian F Guest
Journal:  Eur J Health Econ       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.